Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats.
AUTOR(ES)
Hasegawa, T
RESUMO
The effect of a new quinolone, T-3761, on the pharmacokinetics and metabolism of theophylline was investigated with rats. T-3761 at a high dose (20 mg/kg of body weight) was injected intravenously 10 min before an intravenous administration of theophylline (10 mg/kg). The presence of T-3761 slightly delayed the disappearance of theophylline from plasma. Parameters related to the pharmacokinetic interaction between theophylline and T-3761 were estimated by noncompartmental methods. A significant decrease (approximately 25%) in the systemic clearance of theophylline was observed in the presence of T-3761. However, no significant changes between the control group and the T-3761-treated groups in the volume of distribution at a steady state were observed. Pretreatment with T-3761 increased the urinary excretion of unchanged theophylline (by approximately 25%) and decreased the nonrenal clearances (by approximately 30%), indicating that T-3761 inhibits the metabolism of theophylline. These findings suggest that T-3761 at the dose used in this study affects the pharmacokinetics and metabolism of theophylline.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162897Documentos Relacionados
- In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
- Effect of a New Quinolone, Sparfloxacin, on the Pharmacokinetics of Theophylline in Asthmatic Patients
- Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.
- In vitro activity of T-3761, a new fluoroquinolone.
- Enterohepatic circulation of NY-198, a new difluorinated quinolone, in rats.
